Alternatives to Paige AI

Quibim turns MRI, CT and PET scans into regulatory-cleared quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.

All-in-human AI foundation models for precision neurology — vBx-1.0 predicts brain activity and therapy response from a blood draw.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

Radiology foundation models that turn medical images into complete draft reports for physician review.

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

FDA-cleared echocardiography AI that automates LVEF and screens for cardiac amyloidosis, now backed by a Medicare NTAP.

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

A research-stage AI platform for discovering neurotherapeutics that act on neural circuits across multiple disorders.

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

PicnicAI turns patient health records into clinical research data and real-world evidence.

Open-source Python framework that assembles causal and mechanistic models from literature and biological databases.

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Physics-based molecular simulation with AI for drug discovery and materials design.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

AI protein engineering that optimizes binding, stability, activity, and expression across wet-lab rounds.

Cellino's AI-guided optical bioprocessing automates personalized cell therapy manufacturing on the Nebula™ platform.

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

Dotmatics Luma Agent: agentic AI for regulated R&D that plans, executes, and documents scientific data analysis

AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.